Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection.

Teschner S, Gerke P, Geyer M, Wilpert J, Krumme B, Benzing T, Walz G.

Transplant Proc. 2009 Jul-Aug;41(6):2533-8. doi: 10.1016/j.transproceed.2009.06.099.

PMID:
19715969
2.

Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection.

Krisl JC, Taber DJ, Pilch N, Chavin K, Bratton C, Thomas B, McGillicuddy J, Baliga P.

Clin J Am Soc Nephrol. 2012 Jun;7(6):1003-9. doi: 10.2215/CJN.12531211. Epub 2012 Mar 29.

3.

Polyoma BK virus-associated nephropathy in kidney-transplant patients: Effects of leflunomide on T-cell functions and disease outcome.

Canivet C, Rostaing L, Galvani S, Böhler T, Gandia P, Mengelle C, Guilbeau-Frugier C, Thomsen M, Salvayre R, Negre-Salvayre A, Kamar N.

Int Immunopharmacol. 2009 Aug;9(9):1131-6. doi: 10.1016/j.intimp.2009.05.004. Epub 2009 May 13.

PMID:
19446045
4.

Contrasting patterns of viral load response in transplant recipients with BK polyomavirus DNAemia on leflunomide therapy.

Cuellar-Rodriguez J, Stephany B, Poggio E, Mossad SB, Goldfarb D, Lard M, Askar M, Fatica R, Srinivas T, Braun W, Shoskes D, Flechner S, Schmitt SK, Shrestha R, Avery RK.

Clin Transplant. 2013 May-Jun;27(3):E230-6. doi: 10.1111/ctr.12110. Epub 2013 Apr 3.

PMID:
23551281
5.

[Oscillation between BK virus nephropathy and rejection--the frustrating course of a living donor transplantation].

Materne C, Gerth J, Ott U, Gröne HJ, Wolf G.

Med Klin (Munich). 2009 Aug;104(8):644-8. doi: 10.1007/s00063-009-1136-1. Epub 2009 Aug 23. German.

PMID:
19701735
6.

Active management versus minimization of immunosuppressives of BK virus-associated nephropathy after a kidney transplant.

Halim MA, Al-Otaibi T, Gheith O, Zkaria Z, Mosaad A, Said T, Nair P, Nampoory N.

Exp Clin Transplant. 2014 Dec;12(6):528-33.

7.

Combination of Leflunomide and Everolimus for treatment of BK virus nephropathy.

Jaw J, Hill P, Goodman D.

Nephrology (Carlton). 2017 Apr;22(4):326-329. doi: 10.1111/nep.12948.

PMID:
28247521
8.

Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation.

Faguer S, Hirsch HH, Kamar N, Guilbeau-Frugier C, Ribes D, Guitard J, Esposito L, Cointault O, Modesto A, Lavit M, Mengelle C, Rostaing L.

Transpl Int. 2007 Nov;20(11):962-9. Epub 2007 Jul 30.

9.

Treatment of renal allograft polyoma BK virus infection with leflunomide.

Josephson MA, Gillen D, Javaid B, Kadambi P, Meehan S, Foster P, Harland R, Thistlethwaite RJ, Garfinkel M, Atwood W, Jordan J, Sadhu M, Millis MJ, Williams J.

Transplantation. 2006 Mar 15;81(5):704-10.

PMID:
16534472
10.

Long-Term Follow-Up of Active Treatment Versus Minimization of Immunosuppressive Agents in Patients With BK Virus-Associated Nephropathy After Kidney Transplant.

Halim MA, Al-Otaibi T, Gheith O, Mosaad A, Zakaria Z, Said T, Nair P, Nampoory NM.

Exp Clin Transplant. 2016 Feb;14(1):58-65.

11.

Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients.

Leca N, Muczynski KA, Jefferson JA, de Boer IH, Kowalewska J, Kendrick EA, Pichler R, Davis CL.

Clin J Am Soc Nephrol. 2008 May;3(3):829-35. doi: 10.2215/CJN.03930907. Epub 2008 Mar 27.

12.

Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy.

Saad ER, Bresnahan BA, Cohen EP, Lu N, Orentas RJ, Vasudev B, Hariharan S.

Transplantation. 2008 Mar 27;85(6):850-4. doi: 10.1097/TP.0b013e318166cba8.

PMID:
18360267
13.

Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients.

Araya CE, Garin EH, Neiberger RE, Dharnidharka VR.

Pediatr Transplant. 2010 Feb;14(1):145-50. doi: 10.1111/j.1399-3046.2009.01183.x. Epub 2009 Mar 31.

PMID:
19344337
14.
15.

Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation.

Jung YH, Moon KC, Ha JW, Kim SJ, Ha IS, Cheong HI, Kang HG.

Pediatr Transplant. 2013 Mar;17(2):E50-4. doi: 10.1111/petr.12029. Epub 2012 Dec 4. Review.

PMID:
23210794
16.

Total and free plasma concentrations of the active metabolite of leflunomide in relation to therapeutic outcome in kidney transplant recipients with BK-virus nephropathy.

Hüttemann M, Shipkova M, Klett C, Hasche G, Wilhelm J, Bolley R, Olbricht C, Wieland E.

Transplant Proc. 2013 May;45(4):1611-3. doi: 10.1016/j.transproceed.2012.12.017.

PMID:
23726631
17.

BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen.

Lipshutz GS, Flechner SM, Govani MV, Vincenti F.

Am J Transplant. 2004 Dec;4(12):2132-4.

18.

A single-center experience with BK virus nephropathy.

Ott U, Steiner T, Busch M, Gerth J, Wolf G.

Clin Nephrol. 2008 Apr;69(4):244-50.

PMID:
18397698
19.

Treatment of polyomavirus infection in kidney transplant recipients: a systematic review.

Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA.

Transplantation. 2010 May 15;89(9):1057-70. doi: 10.1097/TP.0b013e3181d0e15e. Review.

PMID:
20090569
20.

Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection.

Liacini A, Seamone ME, Muruve DA, Tibbles LA.

Transplantation. 2010 Dec 27;90(12):1450-7. doi: 10.1097/TP.0b013e3182007be2.

PMID:
21079551

Supplemental Content

Support Center